Global turmoil increases case for EU-UK alignment on medicines security
Mark Samuels outlines his argument for greater UK-EU cooperation to ensure that access to medicines across Europe are as shielded as possible... The post Global turmoil increases case for EU-UK…
Read the full articleYou might also wanna read
Five EU countries seek unified response to US and pharma pressure on drug pricing
The U.S. and pharma companies are increasing the pressure on EU countries to pay more for medicines.
UK medicines investment: the case for improving the UK commercial environment
David Watson builds on The King's Fund's explainer on medicines pricing to make the case for policymakers to protect the UK’s position in li

Brexit denies UK children access to life-extending drug for aggressive brain cancer
Exclusive: Experts say Brexit has led to delays in the launch of clinical trials and increased costs for multiple drugs. They are urging the

Brexit denies UK children access to life-extending drug for aggressive brain cancer
Exclusive: Experts say Brexit has led to delays in the launch of clinical trials and increased costs for multiple drugs. They are urging the

David Greene comments on EU-AstraZeneca dispute
AstraZeneca appears to be in danger of breaching its contract to supply the EU, and may have to renegotiate its contract to supply Covid-19
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade

Starmer's US pharma deal criticized as costly threat to NHS and public health
The deal on medicine imports will cost the NHS billions and take funding away from doctors, nurses, cancer scans and the rest, says Guardian

Comments
Sign in to join the conversation.
No comments yet. Be the first.